Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW

• Published in: Journal of clinical oncology Vol. 42; no. 17_suppl; p. LBA4008
• Main Authors: Decaens, Thomas, Kudo, Masatoshi, Qin, Shukui, Fonseca, Leonardo, Sangro, Bruno, Karachiwala, Hatim, Park, Joong-Won, Gane, Edward, Pinter, Matthias, Tai, David, Santoro, Armando, Pizarro, Gonzalo, Chiu, Chang-Fang, Schenker, Michael, He, Aiwu Ruth, Wang, Qi, Stromko, Caitlyn, Hreiki, Joseph, Yau, Thomas
• Format: Journal Article
• Language: English; Japanese
• Published: American Society of Clinical Oncology 10.06.2024

LBA4008Background: First-line therapies based on programmed death ligand 1 (PD-L1) inhibitors are standard of care (SOC) in uHCC and demonstrate improved outcomes over SOR; however, prognosis remains poor and there is an unmet need for alternative therapies with long-term benefits. Second-line NIVO...